Clinical Trial Update: VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita [Phase 3]

View source ↗

Summary

Phase 3 study evaluating PTX022 for Pachyonychia Congenita has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita

Drugs mentioned

• PTX022

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Pachyonychia Congenita | Phase 3 | Status: COMPLETED